AIM: To investigate the relationship between ARID1 A expression and clinicopathologic parameters, as well as its prognostic value, for patients with intrahepatic cholangiocarcinoma(IHCC).METHODS: We assessed ARID1 A p...AIM: To investigate the relationship between ARID1 A expression and clinicopathologic parameters, as well as its prognostic value, for patients with intrahepatic cholangiocarcinoma(IHCC).METHODS: We assessed ARID1 A protein and m RNA expression in IHCC tissues and paracarcinomatous(PC) tissues from 57 patients with IHCC using western blot and quantitative real-time reverse transcription polymerase chain reaction, respectively. We used Fisher's exact and χ2 tests to analyze relationships between clinicopathological parameters and ARID1 A expression. The Kaplan-Meier method and Cox regression were used to analyze survival.RESULTS: The mean ARID1 A protein level in IHCC tissues was 1.16 ± 0.36 relative units(RU), which was significantly lower than that in PC tissues(1.26 ± 0.21 RU, P < 0.01) and NL tissues(1.11 ± 0.31, P < 0.001).The mean ARID1 A m RNA level in IHCC tissues(1.20 ± 0.18) was also lower than that in PC tissues(1.27 ± 0.15, P < 0.001) and normal liver tissues(1.15 ± 0.34, P < 0.001). Low ARID1 A expression was significantly associated with tumor nodules, vein invasion, and recurrence. Median overall survival(OS) and disease-free survival(DFS) for the low ARID1 A expression group was 15.0 and 7.0 mo, respectively, which were significantly shorter than those for the high ARID1 A expression group at 25.0 and 22.0 mo(OS: P < 0.01; DFS: P < 0.001), respectively. Low ARID1 A expression was significantly associated with worse OS(HR = 3.967, 95%CI: 1.299-12.118, P = 0.016) in multivariate analyses.CONCLUSION: Low expression of ARID1 A is associated with poor prognosis in patients with IHCC, and thus may be a potential prognostic biomarker candidate in IHCC.展开更多
AIM: To compare kinesin family member 1B(KIF1B) expression with clinicopathologic parameters and prognosis in hepatocellular carcinoma(HCC) patients.METHODS: KIF1 B protein and m RNA expression was assessed in HCC and...AIM: To compare kinesin family member 1B(KIF1B) expression with clinicopathologic parameters and prognosis in hepatocellular carcinoma(HCC) patients.METHODS: KIF1 B protein and m RNA expression was assessed in HCC and paracarcinomatous(PC) tissues from 68 patients with HCC using Western blot and quantitative real-time reverse transcription-PCR, respectively. Student's t-tests were used to analyze relationships between clinicopathologic parameters and KIF1 B expression, the Kaplan-Meier method was used to analyze survival outcomes, and the log-rank test was used to compare survival differences between groups.RESULTS: Mean protein and m RNA levels of KIF1 B were similar between HCC and PC tissues. However, HCC tissues with vein invasions had significantly lower KIF1 B protein levels compared to those without vein invasions(2.30 ± 0.82 relative units vs 2.77 ± 0.84 relative units, P < 0.05). KIF1 B protein levels in HCC tissues from patients with recurrence during the followup period were significantly lower than those without recurrence(2.31 ± 0.92 relative units vs 2.80 ± 0.80 relative units, P < 0.05). However, KIF1 B protein and m RNA expression in HCC patients was not associated with other clinicopathologic parameters. Ratios of KIF1 B m RNA expression in HCC tissues to those in PC tissues were correlated with overall survival(13.5 mo vs 20.0 mo, P < 0.05) and disease-free survival(11.5 mo vs 19.5 mo, P < 0.05).CONCLUSION: Downregulation of KIF1 B in HCC tissues is associated with poor prognosis; additional clinical studies are needed to confirm whether KIF1 B can serve as a prognostic marker.展开更多
文摘AIM: To investigate the relationship between ARID1 A expression and clinicopathologic parameters, as well as its prognostic value, for patients with intrahepatic cholangiocarcinoma(IHCC).METHODS: We assessed ARID1 A protein and m RNA expression in IHCC tissues and paracarcinomatous(PC) tissues from 57 patients with IHCC using western blot and quantitative real-time reverse transcription polymerase chain reaction, respectively. We used Fisher's exact and χ2 tests to analyze relationships between clinicopathological parameters and ARID1 A expression. The Kaplan-Meier method and Cox regression were used to analyze survival.RESULTS: The mean ARID1 A protein level in IHCC tissues was 1.16 ± 0.36 relative units(RU), which was significantly lower than that in PC tissues(1.26 ± 0.21 RU, P < 0.01) and NL tissues(1.11 ± 0.31, P < 0.001).The mean ARID1 A m RNA level in IHCC tissues(1.20 ± 0.18) was also lower than that in PC tissues(1.27 ± 0.15, P < 0.001) and normal liver tissues(1.15 ± 0.34, P < 0.001). Low ARID1 A expression was significantly associated with tumor nodules, vein invasion, and recurrence. Median overall survival(OS) and disease-free survival(DFS) for the low ARID1 A expression group was 15.0 and 7.0 mo, respectively, which were significantly shorter than those for the high ARID1 A expression group at 25.0 and 22.0 mo(OS: P < 0.01; DFS: P < 0.001), respectively. Low ARID1 A expression was significantly associated with worse OS(HR = 3.967, 95%CI: 1.299-12.118, P = 0.016) in multivariate analyses.CONCLUSION: Low expression of ARID1 A is associated with poor prognosis in patients with IHCC, and thus may be a potential prognostic biomarker candidate in IHCC.
文摘AIM: To compare kinesin family member 1B(KIF1B) expression with clinicopathologic parameters and prognosis in hepatocellular carcinoma(HCC) patients.METHODS: KIF1 B protein and m RNA expression was assessed in HCC and paracarcinomatous(PC) tissues from 68 patients with HCC using Western blot and quantitative real-time reverse transcription-PCR, respectively. Student's t-tests were used to analyze relationships between clinicopathologic parameters and KIF1 B expression, the Kaplan-Meier method was used to analyze survival outcomes, and the log-rank test was used to compare survival differences between groups.RESULTS: Mean protein and m RNA levels of KIF1 B were similar between HCC and PC tissues. However, HCC tissues with vein invasions had significantly lower KIF1 B protein levels compared to those without vein invasions(2.30 ± 0.82 relative units vs 2.77 ± 0.84 relative units, P < 0.05). KIF1 B protein levels in HCC tissues from patients with recurrence during the followup period were significantly lower than those without recurrence(2.31 ± 0.92 relative units vs 2.80 ± 0.80 relative units, P < 0.05). However, KIF1 B protein and m RNA expression in HCC patients was not associated with other clinicopathologic parameters. Ratios of KIF1 B m RNA expression in HCC tissues to those in PC tissues were correlated with overall survival(13.5 mo vs 20.0 mo, P < 0.05) and disease-free survival(11.5 mo vs 19.5 mo, P < 0.05).CONCLUSION: Downregulation of KIF1 B in HCC tissues is associated with poor prognosis; additional clinical studies are needed to confirm whether KIF1 B can serve as a prognostic marker.
